Wedge Capital Management’s Pacira BioSciences PCRX Stock Holding History

Wedge Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.4M	Buy	+94,554	New	+$2.23M	0.04%	308
2024 Q4	–	Sell	-119,447	Closed	-$1.8M	–	525
2024 Q3	$1.8M	Buy	119,447 +67,947	+132%	+$1.16M	0.03%	344
2024 Q2	$1.47M	Sell	51,500 -4,883	-9%	-$139K	0.03%	349
2024 Q1	$1.65M	Buy	56,383 +24,969	+79%	+$767K	0.03%	346
2023 Q4	$1.06M	Buy	+31,414	New	+$919K	0.02%	355

Other funds holding PCRX

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $77B AUM 50.57% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

1620 Investment Advisors Plymouth, Massachusetts $161M AUM 30.15% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return

JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return